Dr. Alan Nelson, Founder, Chairman and CEO of VisionGate, has overall responsibility for the strategic direction and long-term vision of the company. Dr. Nelson, prior Executive Director, The Biodesign Institute at Arizona State University, is now leading the Predictive Health Analytics Initiative (PHAIT3). Dr. Nelson has also been appointed in two faculty positions; Professor of Bioengineering and Professor of Physics at Arizona State University.
Prior to VisionGate, Dr. Nelson was the founder, President and CEO of NeoPath where he developed the world’s first automated cytology platform. Neopath won landmark FDA approval in 1995 and introduced the AutoPap, a fully automated instrument for primary screening of Pap smears. After a successful Initial Public Offering in 1996, Neopath was sold to Becton Dickinson in 2000.
Before coming to ASU, Dr. Nelson was also a tenured Associate Professor and Director of the Center for Imaging Systems Optimization and the Medical Imaging Graduate Program at the University of Washington. Additionally, he was an Associate Professor with joint appointments at MIT and Harvard where he held the W.M. Keck Foundation endowed chair and directed the Radiological Sciences Program.
Dr. Nelson holds over thirty US patents and has over 100 peer reviewed publications in the field of biomedical imaging. He received his PhD in Biophysics from the University of California, Berkeley.